Patents Assigned to Celtrix Pharmaceuticals, Inc.
-
Patent number: 7288516Abstract: New methods for the treatment of cancer are provided. Null IGF (IGF variants with reduced receptor binding) is administered to subjects having cancer, thereby alleviating the symptoms of the cancer.Type: GrantFiled: September 20, 1999Date of Patent: October 30, 2007Assignee: Celtrix Pharmaceuticals, Inc.Inventor: Desmond Mascarenhas
-
Patent number: 6518238Abstract: Methods are provided for treating or alleviating the symptoms of subjects with psychological disorders, metabolic disorders, chronic stress-related disorders, sleep disorders, conditions associated with sexual senescence, aging, or premature aging by treating such subjects with IGF or mutant IGF either alone or complexed with IGFBP-3. Methods for increasing the levels of DHEA or DHEAS and treating or alleviating the symptoms of subjects with disorders characterized by low levels of DHEA or DHEAS by administering effective amounts of IGF or mutant IGF alone or complexed with IGFBP-3 are also provided. Methods for increasing the level of T4 and treating or alleviating the symptoms of subjects with disorders characterized by low levels of T3 or T4 by administering effective amounts of IGF or mutant IGF alone or complexed with IGFBP-3 are additionally provided.Type: GrantFiled: October 15, 1999Date of Patent: February 11, 2003Assignee: Celtrix Pharmaceuticals, Inc.Inventor: Desmond Mascarenhas
-
Patent number: 6514937Abstract: Methods are provided for treating or alleviating the symptoms of subjects with psychological disorders, metabolic disorders, chronic stress-related disorders, sleep disorders, conditions associated with sexual senescence, aging, or premature aging by treating such subjects with IGF or mutant IGF either alone or complexed with IGFBP-3. Methods for increasing the levels of DHEA or DHEAS and treating or alleviating the symptoms of subjects with disorders characterized by low levels of DHEA or DHEAS by administering effective amounts of IGF or mutant IGF alone or complexed with IGFBP-3 are also provided. Methods for increasing the level of T4 and treating or alleviating the symptoms of subjects with disorders characterized by low levels of T3 or T4 by administering effective amounts of IGF or mutant IGF alone or complexed with IGFBP-3 are additionally provided. Also provided are methods for the treatment of polycystic ovarian syndrome (PCOS) by long term administration of IGF/IGFBP-3 complex.Type: GrantFiled: July 27, 1998Date of Patent: February 4, 2003Assignee: Celtrix Pharmaceuticals, Inc.Inventor: Desmond Mascarenhas
-
Patent number: 6436897Abstract: New pharmaceutical formulations for IGF/IGFBP complex are disclosed. IGF/IGFBP complex, preferably rhIGF-I/IGFBP-3 complex is formulated with bulking agents and optionally buffer salts, but without added osmolyte salts. Also disclosed are lyophilized formulations for IGF/IGFBP complex.Type: GrantFiled: June 1, 1998Date of Patent: August 20, 2002Assignee: Celtrix Pharmaceuticals, Inc.Inventors: Stephen Danko, David Passmore, Yasushi Ogawa
-
Patent number: 6417330Abstract: The invention relates to variants of native insulin-like growth factor binding protein 3 (IGFBP-3). Variant IGFBP-3s are disclosed which are modified to be resistant to hydrolysis. Also disclosed are variant IGFBP-3s where the nuclear localization signal (NLS) in native IGFBP-3 is altered. Additionally, amino-terminally extended IGFBP-3s are disclosed which include a variety of N-terminal extensions, including peptide and nucleotide binding domains, specific binding members such as ligand binding domains from receptors or antigen binding domains from immunoglobins, and peptide and protein hormones and growth factors. N-terminally extended IGFBP-3s may comprise hydrolysis-resistant or NLS variant IGFBP-3s.Type: GrantFiled: May 27, 1999Date of Patent: July 9, 2002Assignee: Celtrix Pharmaceuticals, Inc.Inventors: Desmond Mascarenhas, David Passmore, Stephen Danko
-
Publication number: 20020072589Abstract: The invention relates to variants of native insulin-like growth factor binding protein 3 (IGFBP-3). Variant IGFBP-3s are disclosed which are modified to be resistant to hydrolysis. Also disclosed are variant IGFBP-3s where the nuclear localization signal (NLS) in native IGFBP-3 is altered. Additionally, amino-terminally extended IGFBP-3s are disclosed which include a variety of N-terminal extensions, including peptide and nucleotide binding domains, specific binding members such as ligand binding domains from receptors or antigen binding domains from immunoglobins, and peptide and protein hormones and growth factors. N-terminally extended IGFBP-3s may comprise hydrolysis-resistant or NLS variant IGFBP-3s.Type: ApplicationFiled: November 13, 2001Publication date: June 13, 2002Applicant: Celtrix Pharmaceuticals, Inc.Inventors: Desmond Mascarenhas, David Passmore, Stephen Danko
-
Publication number: 20010034433Abstract: This invention relates to polypeptides that are human somatomedin carrier protein subunits and to processes for producing them. The carrier protein subunits bind to human somatomedin-like polypeptides, also known as insulin-like growth factors. The process involves preparation from a human serum fraction, Cohn IV-1, by a molecule of various chromatographic steps.Type: ApplicationFiled: May 29, 2001Publication date: October 25, 2001Applicant: Celtrix Pharmaceuticals, Inc.Inventors: Emerald Martin Spencer, Carol Talkington-Verser
-
Patent number: 6124259Abstract: This is a method for treating ophthalmic disorders associated with an excess of IGF-I or IGF-II. The method comprises administering individuals with an IGF excess insulin-like growth factor binding protein (IGFBP). The preferred form is IGFBP-3.Type: GrantFiled: February 24, 1998Date of Patent: September 26, 2000Assignee: Celtrix Pharmaceuticals, Inc.Inventors: Michael J. Delmage, Andreas Sommer
-
Patent number: 6087090Abstract: Methods are provided for formulating models for predicting whether subjects will respond to a particular drug or treatment regimen. Biochemical profiles are obtained (by measuring a variety or biochemical parameters) for a test group before and after treatment with the drug or regimen. These values are used formulate a specific predictive method for the particular drug or treatment regimen. The predictive measurement is then used with biochemical parameters obtained from a subject to predict whether that subject will respond to the particular drug or treatment regimen. The predictive methods may also be used to determine the equivalence of different dosages of a drug.Type: GrantFiled: July 27, 1998Date of Patent: July 11, 2000Assignee: Celtrix Pharmaceuticals, Inc.Inventor: Desmond Mascarenhas
-
Patent number: 6040292Abstract: The invention provides new methods for the treatment of diabetes mellitus, including type I, type II, and insulin resistant diabetes (both type I and type II). The methods of the invention employ administration of rhIGF-I/IGFBP-3 complex to a subject suffering from the symptoms of diabetes mellitus. Administration of rhIGF-I/IGFBP-3 to a subject suffering from the symptoms of diabetes mellitus results in amelioration or stabilization of the symptoms of diabetes.Type: GrantFiled: June 4, 1999Date of Patent: March 21, 2000Assignee: Celtrix Pharmaceuticals, Inc.Inventor: Andreas Sommer
-
Patent number: 6025368Abstract: Methods are provided for treating or alleviating the symptoms of subjects with psychological disorders, metabolic disorders, chronic stress-related disorders, sleep disorders, conditions associated with sexual senescence, aging, or premature aging by treating such subjects with IGF either alone or complexed with IGFBP-3. Methods for increasing the levels of DHEA or DHEAS and treating or alleviating the symptoms of subjects with disorders characterized by low levels of DHEA or DHEAS by administering effective amounts of IGF alone or complexed with IGFBP-3 are also provided. Methods for increasing the level of T4 and treating or alleviating the symptoms of subjects with disorders characterized by low levels of T3 or T4 by administering effective amounts of IGF alone or complexed with IGFBP-3 are additionally provided.Type: GrantFiled: February 25, 1997Date of Patent: February 15, 2000Assignee: Celtrix Pharmaceuticals, Inc.Inventors: Desmond Mascarenhas, Martin Sanders
-
Patent number: 6025332Abstract: Methods are provided for treating or alleviating the symptoms of subjects with psychological disorders, metabolic disorders, chronic stress-related disorders, sleep disorders, conditions associated with sexual senescence, aging, or premature aging by treating such subjects with IGF or mutant IGF either alone or complexed with IGFBP-3. Methods for increasing the levels of DHEA or DHEAS and treating or alleviating the symptoms of subjects with disorders characterized by low levels of DHEA or DHEAS by administering effective amounts of IGF or mutant IGF alone or complexed with IGFBP-3 are also provided. Methods for increasing the level of T4 and treating or alleviating the symptoms of subjects with disorders characterized by low levels of T3 or T4 by administering effective amounts of IGF or mutant IGF alone or complexed with IGFBP-3 are additionally provided.Type: GrantFiled: June 1, 1998Date of Patent: February 15, 2000Assignee: Celtrix Pharmaceuticals, Inc.Inventor: Desmond Mascarenhas
-
Patent number: 6017885Abstract: IGF and IGFBP are administered to stimulate new bone formation in subjects with bone loss due to bone marrow disorders, connective tissue disorders, drugs, pregnancy, lactation, chronic hypophosphatemia, hyperphosphatasia, insulin-dependent diabetes mellitus, anorexia nervosa, cadmium poisoning, juvenile osteoporosis, Paget's disease of bone, osteoarthritis and periodontal disease. IGF-I and IGFBP-3 are optionally combined with agents that inhibit bone resorption.Type: GrantFiled: May 14, 1998Date of Patent: January 25, 2000Assignee: Celtrix Pharmaceuticals, Inc.Inventors: Cedo Martin Bagi, Robert Brommage, David M. Rosen, Steven W. Adams
-
Patent number: 6015786Abstract: Methods are provided for treating or alleviating the symptoms of subjects with psychological disorders, metabolic disorders, chronic stress-related disorders, sleep disorders, conditions associated with sexual senescence, aging, or premature aging by treating such subjects with IGF or mutant IGF either alone or complexed with IGFBP-3. Methods for increasing the levels of DHEA or DHEAS and treating or alleviating the symptoms of subjects with disorders characterized by low levels of DHEA or DHEAS by administering effective amounts of IGF or mutant IGF alone or complexed with IGFBP-3 are also provided. Methods for increasing the level of T4 and treating or alleviating the symptoms of subjects with disorders characterized by low levels of T3 or T4 by administering effective amounts of IGF or mutant IGF alone or complexed with IGFBP-3 are additionally provided.Type: GrantFiled: April 21, 1997Date of Patent: January 18, 2000Assignee: Celtrix Pharmaceuticals, Inc.Inventors: Desmond Mascarenhas, Martin Sanders
-
Patent number: 5948757Abstract: The present invention involves a method for providing high dose IGF-I therapy by administering a complex of IGF-I and IGFBP-3. The IGF-I/IGFBP-3 complex may be given at unexpectedly high doses without inducing IGF-I-related side effects.Type: GrantFiled: March 1, 1996Date of Patent: September 7, 1999Assignee: Celtrix Pharmaceuticals, Inc.Inventors: Andreas Sommer, Jerome A. Moore, Steven Adams
-
Patent number: 5914390Abstract: Methods are disclosed for increasing the yields of recombinant proteins. Addition of one or more protective agents, such as a sulfated compound (including heparin, heparin sulfate, sodium dodecyl sulfate, and the like), hyaluronic acid or deoxycholate, to recombinant protein production processes is disclosed. Addition of protective agents to the recombinant production process results in increased yields of recombinant proteins.Type: GrantFiled: May 12, 1997Date of Patent: June 22, 1999Assignee: Celtrix Pharmaceuticals, Inc.Inventors: Ranga Nathan, Henryk Cudny
-
Patent number: 5914254Abstract: The invention is directed to the use of a fusion partner that does not contain a leader sequence, as a means to increase the solubility and activity of recombinant polypeptides by facilitating the expression of fusion proteins, which are then transported out of the cytoplasm. The invention includes a nucleic acid encoding a fusion polypeptide comprising a mature interleukin-1-like polypeptide or a leader-deleted-translocating polypeptide, and a polypeptide of interest; as well as host cells comprising such nucleic acids, and fusion proteins so encoded. The invention also encompasses methods of using such nucleic acids to produce recombinant fusion polypeptides, mature polypeptides of interest, and purified compositions thereof.Type: GrantFiled: May 12, 1997Date of Patent: June 22, 1999Assignee: Celtrix Pharmaceuticals, Inc.Inventors: Desmond Mascarenhas, Yang Zhang, Pamela S. Olson, David R. Olsen, Pedro A. Cohen, Kimyen B. Nguyen
-
Patent number: 5830706Abstract: The invention is directed to the use of IL-1-like fusion polypeptides to increase the solubility and activity of recombinant polypeptides. The invention includes a nucleic acid encoding a fusion polypeptide comprising an interleukin-1-like polypeptide and a polypeptide of interest and the method of using such a nucleic acid to produce recombinant fusion polypeptides.Type: GrantFiled: June 5, 1995Date of Patent: November 3, 1998Assignee: Celtrix Pharmaceuticals, Inc.Inventors: Desmond Mascarenhas, Yang Zhang, Pamela S. Olson, David R. Olsen, Pedro A. Carrillo
-
Patent number: 5789547Abstract: The present invention provides a novel method for refolding insulin-like growth factor I (IGF-I) and insulin-like growth factor binding protein 3(IGFBP-3). The method involves mixing of IGF-I and IGFBP-3 together in a cofolding reaction. The inventive cofolding method results in substantially higher yields of correctly folded protein for both molecules and alters the kinetics of refolding. The method includes the production of correctly folded IGF-I, IGFBP-3, and/or IGF-I/IGFBP-3 complex.Type: GrantFiled: June 7, 1995Date of Patent: August 4, 1998Assignee: Celtrix Pharmaceuticals, Inc.Inventors: Andreas Sommer, Yasushi Ogawa, Peggy Tao
-
Patent number: 5783185Abstract: Monoclonal antibodies to transforming growth factor beta (TGF-B) are prepared from hybrid cell lines by immunizing with TGF-B2. The antibodies may be of any isotype and may be of any mammalian origin such as murine or human origin. Therapeutic applications for treating or reducing the likelihood of developing acute or chronic fibrosis utilizing the TGF-B monoclonal antibody are also disclosed.Type: GrantFiled: May 4, 1995Date of Patent: July 21, 1998Assignee: Celtrix Pharmaceuticals, Inc.Inventors: James R. Dasch, Doran R. Pace, III, Wendy O. Waegell